(Persia Digest) – Four anti-cancer and diabetes drugs produced by Iranian researchers have been launched at a ceremony attended by the Deputy Vice President for Science and Technology, Health Minister, and Alborz Province Governor.
The two vital anti-cancer drugs are Regorphanib and Sorafenib. The other two drugs are Empagliflozin and Dapagliflozin which are widely used by diabetes sufferers.
Regorphanib is a significant drug used by patients who suffer from colon, stomach, and liver cancer which has been produced solely in Germany to date. A box of 28 pills costs USD 5870 on global markets (tomans 82MM on the free forex market in Iran). The Iranian version of the drug with a similar or better quality is now available in Iran at 5 percent of the German version.
This drug was first marketed in 2010. Iranian researchers have now deciphered its complicated technology after seven years of experimentation.
Sorafenib is used in the treatment of advanced liver, kidney, and thyroid cancer. So far, this has been produced only in Germany and the US, available at a cost of USD 4880 (tomans 68 MM on the free forex market in Iran). A good quality version is now available on the Iranian market at less than one-tenth of the global price.
Empagliflozin is the first diabetes drug in the world which can reduce the death rate among adults suffers of type 2 diabetes. This has been in the monopoly of Germany and the US. Iran is now the third producing country.
Dapagliflozin is also used to treat diabetes mellitus type II. Iran is now the second country to produce this after the UK. The price in Iran will be only 2 percent of the price on the global market.
The above two drugs were marketed in 2014 and Iran has been able to produce them five years later.
Click here for more SciTech news.